Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

BAYLOR COLLEGE OF MEDICINE

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1900-10-30

Employees: 10K

Market Cap: -

Website: http://www.bcm.edu

Clinical Trials

Effectiveness of Ultrasound (US) Guided Supraclavicular Block

Not Applicable

Withdrawn

Conditions: Pain
Analgesia

Interventions: Drug: 20 ml of ropivacaine 0.5%
Drug: 30 ml of ropivacaine 0.5%
Drug: 40 ml of ropivacaine 0.5%

First Posted Date: 2009-06-18

Last Posted Date: 2017-01-20

Lead Sponsor: Baylor College of Medicine

Registration Number: NCT00923494

Locations: 🇺🇸
Ben Taub General Hospital, Houston, Texas, United States

A Study of Bevacizumab to Prevent Malignant Ascites

Phase 2

Withdrawn

Conditions: Malignant Ascites

Interventions: Drug: Bevacizumab

First Posted Date: 2009-05-25

Last Posted Date: 2015-06-03

Lead Sponsor: Baylor College of Medicine

Registration Number: NCT00908219

Locations: 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸
Ben Taub General Hospital, Houston, Texas, United States
🇺🇸
Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, United States

Amitiza in Constipation Associated With PD (Parkinson's Disease)

Phase 4

Completed

Conditions: Parkinson's Disease

Interventions: Drug: LUBIPROSTONE

First Posted Date: 2009-05-25

Last Posted Date: 2022-12-29

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 78

Registration Number: NCT00908076

Locations: 🇺🇸
University of South Florida, Tampa, Florida, United States
🇺🇸
Baylor College of Medicine PDCMDC, Houston, Texas, United States

Study of the Safety and Efficacy of Botox in Bruxism

Phase 4

Completed

Conditions: Bruxism

Interventions: Drug: Placebo arm
Drug: Botulinum toxin type A

First Posted Date: 2009-05-25

Last Posted Date: 2023-06-18

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 23

Registration Number: NCT00908050

Locations: 🇺🇸
Baylor College of Medicine, Houston, Texas, United States

Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma

Phase 1

Active, not recruiting

Conditions: Sarcoma

Interventions: Genetic: Autologous HER2-specific T cells
Drug: Fludarabine
Drug: Cyclophosphamide
Genetic: Autologous CAR Positive T cells

First Posted Date: 2009-05-14

Last Posted Date: 2024-12-27

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 36

Registration Number: NCT00902044

Locations: 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Prevention of Recurrent Infections Caused by Community Acquired Staphylococcus Aureus (CA-SA) in Children

Not Applicable

Completed

Conditions: Community-Acquired Staphylococcus Aureus

Interventions: Procedure: Routine Measures Group
Procedure: Bleach Bath Group (Bleach plus routine measures)

First Posted Date: 2009-05-13

Last Posted Date: 2016-11-06

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 987

Registration Number: NCT00901316

Locations: 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Her2 and TGFBeta Cytotoxic T Cells in Treatment of Her2 Positive Malignancy

Phase 1

Completed

Conditions: HER2 Positive Malignancies

Interventions: Biological: TGFBeta resistant HER2/EBV-CTLs

First Posted Date: 2009-04-29

Last Posted Date: 2018-09-18

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 20

Registration Number: NCT00889954

Locations: 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL

Phase 1

Recruiting

Conditions: Leukemia
Lymphoma
Myeloma

Interventions: Biological: Kappa CD28 T cells

First Posted Date: 2009-04-15

Last Posted Date: 2025-02-07

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 54

Registration Number: NCT00881920

Locations: 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States

The Efficacy of Doxazosin for Cocaine Users

Phase 1

Completed

Conditions: Cocaine Dependence

Interventions: Other: Placebo
Drug: Doxazosin

First Posted Date: 2009-04-14

Last Posted Date: 2019-08-22

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 35

Registration Number: NCT00880997

Locations: 🇺🇸
Baylor College of Medicine - Michael E. DeBakey VA Medical Center, Houston, Texas, United States

Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus

Phase 1

Completed

Conditions: Cytomegalovirus Infection
Adenovirus Infection

Interventions: Biological: CMV/AdV specific T cells

First Posted Date: 2009-04-14

Last Posted Date: 2014-10-15

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 9

Registration Number: NCT00880789

Locations: 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy